Haploinsufficiency
Definition
Haploinsufficiency is a mechanism of pathogenicity in which a single functional copy of a gene is insufficient to maintain normal protein levels and cellular function. In cardiac genetics, it arises from truncating mutations (nonsense, frameshift, splice-site) that produce mRNAs or truncated proteins rapidly cleared by cellular quality-control pathways — principally nonsense-mediated mRNA decay (NMD), the ubiquitin-proteasome system (UPS), and the autophagy-lysosome pathway — leaving only the wild-type allele product at approximately half-normal levels.
Key Concepts
Cellular Mechanisms of Truncated Protein Clearance
- Nonsense-mediated mRNA decay (NMD): Degrades mRNAs containing premature termination codons prior to translation; the dominant clearance mechanism for the majority of truncating variants. (sources/mybpc3-gene-2015 — medium)
- Ubiquitin-proteasome system (UPS): Degrades misfolded or truncated proteins that escape NMD; impaired UPS from cumulative load (ageing, neurohumoral stress) compounds pathology in HCM. (sources/mybpc3-gene-2015)
- Autophagy-lysosome pathway: Secondary protein clearance mechanism, important when UPS capacity is exceeded.
MYBPC3 — Canonical Cardiac Haploinsufficiency
-
60% of pathogenic MYBPC3 mutations are truncating; Western blot of human HCM myocardium and heterozygous knock-in mice shows no detectable truncated protein. Only the wild-type allele product is present, at approximately half-normal levels. (sources/mybpc3-gene-2015 — medium)
- Functional consequence: Reduced cMyBP-C → increased myofilament Ca²⁺ sensitivity, impaired diastolic relaxation, and accelerated crossbridge cycling — even before overt hypertrophy develops. (sources/mybpc3-gene-2015)
- Bi-allelic truncating mutations (both alleles affected): All 26 reported cases led to neonatal cardiomyopathy → heart failure and death within the first year of life; cardiac transplantation is the only curative option. (sources/mybpc3-gene-2015)
Contrast with Dominant-Negative (Missense) Mechanism
- Missense mutations produce stable mutant proteins that can be incorporated into the sarcomere as "poison polypeptides," disrupting sarcomeric architecture and/or function.
- The therapeutic distinction is critical: haploinsufficiency is addressed by restoring protein levels (gene replacement, exon skipping to restore reading frame); dominant-negative requires gene silencing or specific allele ablation. Per-variant mechanistic characterisation is not routinely performed in clinical practice. (sources/mybpc3-gene-2015)
Haploinsufficiency in Other Cardiac Conditions
- SCN5A (LOF) in Brugada syndrome: Truncating SCN5A mutations reduce Nav1.5 surface expression → haploinsufficiency of the sodium channel → reduced INa in the RV epicardium. Pathway-level compensation (e.g., MOG1 overexpression to enhance Nav1.5 trafficking) offers a workaround without replacing full-length SCN5A. (sources/gene-therapy-arrhythmia-2025)
- CASQ2 in CPVT2: Autosomal recessive — both alleles affected; insufficient calsequestrin → aberrant SR Ca²⁺ release. CASQ2 AAV gene replacement is the most clinically advanced inherited CPVT gene therapy. (sources/channelopathies-jaha-2025)
Therapeutic Implications
- Gene replacement (AAV): Restores WT protein expression directly — dose-dependently prevented cardiac hypertrophy and dysfunction over 34 weeks in homozygous Mybpc3 knock-in mice. (sources/mybpc3-gene-2015)
- Exon skipping (AON/AAV): Removes the exon(s) containing the mutation to restore the reading frame → smaller in-frame protein with preserved key domains — demonstrated in heterozygous Mybpc3 knock-in newborn mice. (sources/mybpc3-gene-2015)
- Haploinsufficiency makes the mutant allele a less compelling target for gene silencing; the primary therapeutic goal is upregulating or replacing WT protein function. (sources/mybpc3-gene-2015)
Contradictions / Open Questions
- Haploinsufficiency vs dominant-negative — not always distinguishable per variant: Truncating variants generally produce haploinsufficiency (confirmed by undetectable truncated protein). Some missense variants produce stable dominant-negative proteins. Distinguishing the mechanism requires per-variant Western blot analysis — not routinely performed clinically. (sources/mybpc3-gene-2015)
- UPS impairment as disease amplifier: Stressors impair UPS in Mybpc3 mutant mice — a vicious cycle where reduced clearance of misfolded proteins generates proteotoxic stress. Human clinical correlates are limited. (sources/mybpc3-gene-2015)
Connections
- Related to entities/MYBPC3
- Related to entities/HCM
- Related to concepts/Sarcomere-Biology
- Related to concepts/AAV-Gene-Delivery
- Related to concepts/Gene-Editing-Risk-Benefit-Framework
- Related to concepts/Gene-Silencing-Therapy